Vaccines Market Size and Growth 2031
Vaccines Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Type (Conjugated Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Toxoid Vaccines), Indication (HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Others), Route of Administration (Injection, Oral, and Other), Age Group (Pediatric and Adult), and Geography
- Status : Published
- Report Code : TIPRE00015468
- Category : Life Sciences
- No. of Pages : 150
- Available Report Formats :
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Technology, Application, Route of Administration, End User, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
North America dominated the market in 2024.
The growing incidences of infectious diseases and disease outbreaks, and surging immunization programs and government initiatives contribute to market growth.
GlaxoSmithKline plc, Sanofi SA, CSL Seqirus, Abbott, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd, Pfizer Inc., Mylan NV, Novartis, and Merck are among the key players operating in the vaccines market.
The market is expected to reach US$ 118.94 billion by 2031.
The market is estimated to register a CAGR of 5.7% during the forecast period.
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Analyst Market Outlook
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
3.3 Assumptions and Limitations
4. Vaccines Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Vaccines Market – Key Market Dynamics
5.1 Vaccines Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Growing Incidences of Infectious Diseases and Disease Outbreaks
5.2.2 Surging Immunization Programs and Government Initiatives
5.3 Market Restraints
5.3.1 High Vaccine Development Cost and Increased Time to Market
5.4 Market Opportunities
5.4.1 Development of Combination and Therapeutic Vaccines
5.5 Future Trends
5.5.1 Integration of Artificial Intelligence and Big Data in Vaccine Development
5.6 Impact of Drivers and Restraints:
6. Vaccines Market - Global Market Analysis
6.1 Vaccines - Global Market Overview
6.2 Vaccines - Global Market and Forecast to 2031
7. Vaccines Market – Revenue Analysis (USD Million) – By Technology, 2020-2031
7.1 Overview
7.2 Live Attenuated Vaccines
7.1.1 Overview
7.1.2 Live Attenuated Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Inactivated Vaccines and Subunit Vaccines
7.2.1 Overview
7.2.2 Inactivated Vaccines and Subunit Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Toxoid Vaccines
7.3.1 Overview
7.3.2 Toxoid Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Conjugate Vaccines
7.3.1 Overview
7.3.2 Conjugate Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Recombinant Vaccines
7.3.1 Overview
7.3.2 Recombinant Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.7 Others
8. Vaccines Market – Revenue Analysis (USD Million) – By Disease Indication, 2020-2031
8.1 Overview
8.2 Influenza
8.1.1 Overview
8.1.2 Influenza: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Dengue
8.1.1 Overview
8.1.2 Dengue: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Cytomegalovirus (CMV)
8.1.1 Overview
8.1.2 Cytomegalovirus (CMV): Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
8.5 Hepatitis
8.1.1 Overview
8.1.2 Hepatitis: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
8.6 Respiratory Synical Virus (RSV)
8.1.1 Overview
8.1.2 Respiratory Synical Virus (RSV): Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
8.7 Other Diseases
8.1.1 Overview
8.1.2 Other Diseases: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
9. Vaccines Market – Revenue Analysis (USD Million) – By Route of Administration, 2020-2031
9.1 Overview
9.1.1 Overview
9.1.2 Oral: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Injectable
9.1.1 Overview
9.1.2 Injectable: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
9.4 Other Route of Administration
9.1.1 Overview
9.1.2 Other Route of Administration: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
10. Vaccines Market – Revenue Analysis (USD Million) – By Patient Type, 2020-2031
10.1 Overview
10.2 Pediatric
10.2.1 Overview
10.2.2 Pediatric: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
10.3 Adult
10.3.1 Overview
10.3.2 Adult: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
11. Vaccines Market - Revenue Analysis (USD Million), 2020-2031 – Geographical Analysis
11.1 North America
11.1.1 North America Vaccines Market Overview
11.1.2 North America Vaccines Market Revenue and Forecasts to 2031
11.1.3 North America Vaccines Market Revenue and Forecasts and Analysis - By Technology
11.1.4 North America Vaccines Market Revenue and Forecasts and Analysis - By Disease Indication
11.1.5 North America Vaccines Market Revenue and Forecasts and Analysis - By Route of Administration
11.1.6 North America Vaccines Market Revenue and Forecasts and Analysis - By Patient Type
11.1.7 North America Vaccines Market Revenue and Forecasts and Analysis - By Countries
11.1.7.1 United States Vaccines Market
11.1.7.1.1 United States Vaccines Market, by Technology
11.1.7.1.2 United States Vaccines Market, by Disease Indication
11.1.7.1.3 United States Vaccines Market, by Route of Administration
11.1.7.1.4 United States Vaccines Market, by Patient Type
11.1.7.2 Canada Vaccines Market
11.1.7.2.1 Canada Vaccines Market, by Technology
11.1.7.2.2 Canada Vaccines Market, by Disease Indication
11.1.7.2.3 Canada Vaccines Market, by Route of Administration
11.1.7.2.4 Canada Vaccines Market, by Patient Type
11.1.7.3 Mexico Vaccines Market
11.1.7.3.1 Mexico Vaccines Market, by Technology
11.1.7.3.2 Mexico Vaccines Market, by Disease Indication
11.1.7.3.3 Mexico Vaccines Market, by Route of Administration
11.1.7.3.4 Mexico Vaccines Market, by Patient Type
Note - Similar analysis would be provided for below mentioned regions/countries
11.2 Europe
10.2.1 Europe Vaccines Market Overview
10.2.2 Europe: Vaccines Market – Revenue, 2021–2031 (US$ Million)
10.2.2.1 Europe: Vaccines Market – Revenue and Forecast Analysis – by Technology
10.2.2.2 Europe: Vaccines Market – Revenue and Forecast Analysis – by Live Attenuated Vaccines
10.2.2.3 Europe: Vaccines Market – Revenue and Forecast Analysis – by Inactivated Vaccines and Subunit Vaccines
10.2.2.4 Europe: Vaccines Market – Revenue and Forecast Analysis – by Disease Indication
10.2.2.5 Europe: Vaccines Market – Revenue and Forecast Analysis – by Influenza
10.2.2.6 Europe: Vaccines Market – Revenue and Forecast Analysis – by Route of Administration
10.2.3 Europe: Vaccines Market – Revenue and Forecast Analysis – by Country
10.2.3.1 Germany: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3.1.1 Germany: Vaccines Market Breakdown, by Technology
10.2.3.1.2 Germany: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.2.3.1.3 Germany: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.2.3.1.4 Germany: Vaccines Market Breakdown, by Disease Indication
10.2.3.1.5 Germany: Vaccines Market Breakdown, by Influenza
10.2.3.1.6 Germany: Vaccines Market Breakdown, by Route of Administration
10.2.3.2 United Kingdom: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3.2.1 United Kingdom: Vaccines Market Breakdown, by Technology
10.2.3.2.2 United Kingdom: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.2.3.2.3 United Kingdom: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.2.3.2.4 United Kingdom: Vaccines Market Breakdown, by Disease Indication
10.2.3.2.5 United Kingdom: Vaccines Market Breakdown, by Influenza
10.2.3.2.6 United Kingdom: Vaccines Market Breakdown, by Route of Administration
10.2.3.3 France: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3.3.1 France: Vaccines Market Breakdown, by Technology
10.2.3.3.2 France: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.2.3.3.3 France: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.2.3.3.4 France: Vaccines Market Breakdown, by Disease Indication
10.2.3.3.5 France: Vaccines Market Breakdown, by Influenza
10.2.3.3.6 France: Vaccines Market Breakdown, by Route of Administration
10.2.3.4 Italy: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3.4.1 Italy: Vaccines Market Breakdown, by Technology
10.2.3.4.2 Italy: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.2.3.4.3 Italy: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.2.3.4.4 Italy: Vaccines Market Breakdown, by Disease Indication
10.2.3.4.5 Italy: Vaccines Market Breakdown, by Influenza
10.2.3.4.6 Italy: Vaccines Market Breakdown, by Route of Administration
10.2.3.5 Spain: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3.5.1 Spain: Vaccines Market Breakdown, by Technology
10.2.3.5.2 Spain: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.2.3.5.3 Spain: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.2.3.5.4 Spain: Vaccines Market Breakdown, by Disease Indication
10.2.3.5.5 Spain: Vaccines Market Breakdown, by Influenza
10.2.3.5.6 Spain: Vaccines Market Breakdown, by Route of Administration
10.2.3.6 Rest of Europe: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3.6.1 Rest of Europe: Vaccines Market Breakdown, by Technology
10.2.3.6.2 Rest of Europe: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.2.3.6.3 Rest of Europe: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.2.3.6.4 Rest of Europe: Vaccines Market Breakdown, by Disease Indication
10.2.3.6.5 Rest of Europe: Vaccines Market Breakdown, by Influenza
10.2.3.6.6 Rest of Europe: Vaccines Market Breakdown, by Route of Administration
10.3 Asia Pacific
10.3.1 Asia Pacific Vaccines Market Overview
10.3.2 Asia Pacific: Vaccines Market – Revenue, 2021–2031 (US$ Million)
10.3.2.1 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Technology
10.3.2.2 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Live Attenuated Vaccines
10.3.2.3 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Inactivated Vaccines and Subunit Vaccines
10.3.2.4 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Disease Indication
10.3.2.5 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Influenza
10.3.2.6 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Route of Administration
10.3.3 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Country
10.3.3.1 China: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3.1.1 China: Vaccines Market Breakdown, by Technology
10.3.3.1.2 China: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.3.3.1.3 China: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.3.3.1.4 China: Vaccines Market Breakdown, by Disease Indication
10.3.3.1.5 China: Vaccines Market Breakdown, by Influenza
10.3.3.1.6 China: Vaccines Market Breakdown, by Route of Administration
10.3.3.2 India: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3.2.1 India: Vaccines Market Breakdown, by Technology
10.3.3.2.2 India: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.3.3.2.3 India: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.3.3.2.4 India: Vaccines Market Breakdown, by Disease Indication
10.3.3.2.5 India: Vaccines Market Breakdown, by Influenza
10.3.3.2.6 India: Vaccines Market Breakdown, by Route of Administration
10.3.3.3 Japan: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3.3.1 Japan: Vaccines Market Breakdown, by Technology
10.3.3.3.2 Japan: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.3.3.3.3 Japan: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.3.3.3.4 Japan: Vaccines Market Breakdown, by Disease Indication
10.3.3.3.5 Japan: Vaccines Market Breakdown, by Influenza
10.3.3.3.6 Japan: Vaccines Market Breakdown, by Route of Administration
10.3.3.4 Australia: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3.4.1 Australia: Vaccines Market Breakdown, by Technology
10.3.3.4.2 Australia: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.3.3.4.3 Australia: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.3.3.4.4 Australia: Vaccines Market Breakdown, by Disease Indication
10.3.3.4.5 Australia: Vaccines Market Breakdown, by Influenza
10.3.3.4.6 Australia: Vaccines Market Breakdown, by Route of Administration
10.3.3.5 South Korea: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3.5.1 South Korea: Vaccines Market Breakdown, by Technology
10.3.3.5.2 South Korea: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.3.3.5.3 South Korea: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.3.3.5.4 South Korea: Vaccines Market Breakdown, by Disease Indication
10.3.3.5.5 South Korea: Vaccines Market Breakdown, by Influenza
10.3.3.5.6 South Korea: Vaccines Market Breakdown, by Route of Administration
10.3.3.6 Rest of APAC: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3.6.1 Rest of APAC: Vaccines Market Breakdown, by Technology
10.3.3.6.2 Rest of APAC: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.3.3.6.3 Rest of APAC: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.3.3.6.4 Rest of APAC: Vaccines Market Breakdown, by Disease Indication
10.3.3.6.5 Rest of APAC: Vaccines Market Breakdown, by Influenza
10.3.3.6.6 Rest of APAC: Vaccines Market Breakdown, by Route of Administration
10.4 Middle East and Africa
10.4.1 Middle East and Africa Vaccines Market Overview
10.4.2 Middle East and Africa: Vaccines Market – Revenue, 2021–2031 (US$ Million)
10.4.2.1 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Technology
10.4.2.2 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Live Attenuated Vaccines
10.4.2.3 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Inactivated Vaccines and Subunit Vaccines
10.4.2.4 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Disease Indication
10.4.2.5 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Influenza
10.4.2.6 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Route of Administration
10.4.3 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Country
10.4.3.1 South Africa: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.3.1.1 South Africa: Vaccines Market Breakdown, by Technology
10.4.3.1.2 South Africa: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.4.3.1.3 South Africa: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.4.3.1.4 South Africa: Vaccines Market Breakdown, by Disease Indication
10.4.3.1.5 South Africa: Vaccines Market Breakdown, by Influenza
10.4.3.1.6 South Africa: Vaccines Market Breakdown, by Route of Administration
10.4.3.2 Saudi Arabia: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.3.2.1 Saudi Arabia: Vaccines Market Breakdown, by Technology
10.4.3.2.2 Saudi Arabia: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.4.3.2.3 Saudi Arabia: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.4.3.2.4 Saudi Arabia: Vaccines Market Breakdown, by Disease Indication
10.4.3.2.5 Saudi Arabia: Vaccines Market Breakdown, by Influenza
10.4.3.2.6 Saudi Arabia: Vaccines Market Breakdown, by Route of Administration
10.4.3.3 United Arab Emirates: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.3.3.1 United Arab Emirates: Vaccines Market Breakdown, by Technology
10.4.3.3.2 United Arab Emirates: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.4.3.3.3 United Arab Emirates: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.4.3.3.4 United Arab Emirates: Vaccines Market Breakdown, by Disease Indication
10.4.3.3.5 United Arab Emirates: Vaccines Market Breakdown, by Influenza
10.4.3.3.6 United Arab Emirates: Vaccines Market Breakdown, by Route of Administration
10.4.3.4 Rest of Middle East and Africa: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.3.4.1 Rest of Middle East and Africa: Vaccines Market Breakdown, by Technology
10.4.3.4.2 Rest of Middle East and Africa: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.4.3.4.3 Rest of Middle East and Africa: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.4.3.4.4 Rest of Middle East and Africa: Vaccines Market Breakdown, by Disease Indication
10.4.3.4.5 Rest of Middle East and Africa: Vaccines Market Breakdown, by Influenza
10.4.3.4.6 Rest of Middle East and Africa: Vaccines Market Breakdown, by Route of Administration
10.5 South and Central America
10.5.1 South and Central America Vaccines Market Overview
10.5.2 South and Central America: Vaccines Market – Revenue, 2021–2031 (US$ Million)
10.5.2.1 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Technology
10.5.2.2 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Live Attenuated Vaccines
10.5.2.3 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Inactivated Vaccines and Subunit Vaccines
10.5.2.4 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Disease Indication
10.5.2.5 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Influenza
10.5.2.6 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Route of Administration
10.5.3 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Country
10.5.3.1 Brazil: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.3.1.1 Brazil: Vaccines Market Breakdown, by Technology
10.5.3.1.2 Brazil: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.5.3.1.3 Brazil: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.5.3.1.4 Brazil: Vaccines Market Breakdown, by Disease Indication
10.5.3.1.5 Brazil: Vaccines Market Breakdown, by Influenza
10.5.3.1.6 Brazil: Vaccines Market Breakdown, by Route of Administration
10.5.3.2 Argentina: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.3.2.1 Argentina: Vaccines Market Breakdown, by Technology
10.5.3.2.2 Argentina: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.5.3.2.3 Argentina: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.5.3.2.4 Argentina: Vaccines Market Breakdown, by Disease Indication
10.5.3.2.5 Argentina: Vaccines Market Breakdown, by Influenza
10.5.3.2.6 Argentina: Vaccines Market Breakdown, by Route of Administration
10.5.3.3 Rest of South and Central America: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.3.3.1 Rest of South and Central America: Vaccines Market Breakdown, by Technology
10.5.3.3.2 Rest of South and Central America: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.5.3.3.3 Rest of South and Central America: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.5.3.3.4 Rest of South and Central America: Vaccines Market Breakdown, by Disease Indication
10.5.3.3.5 Rest of South and Central America: Vaccines Market Breakdown, by Influenza
10.5.3.3.6 Rest of South and Central America: Vaccines Market Breakdown, by Route of Administration
12. Industry Landscape
12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments
13. Competitive Landscape
13.1 Heat Map Analysis by Key Players
13.2 Ranking by Key Players
14. Vaccines Market - Key Company Profiles
14.1 GlaxoSmithKline plc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Sanofi
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Merck and Co., Inc
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Serum Institute of India (SII)
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 BioNTech
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Abbott
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Sinovac
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Novartis
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 CSL Seqirus
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 Glossary
15.2 About The Insight Partners
15.3 Market Intelligence Cloud
List of Tables
Table 1. Vaccines Market Segmentation
Table 2. Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 3. Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 4. North America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 5. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 6. North America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 7. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 8. North America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 9. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 10. North America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 11. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 12. North America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 13. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 14. North America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 15. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 16. United States: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 17. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 18. United States: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 19. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 20. United States: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 21. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 22. United States: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 23. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 24. United States: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 25. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 26. United States: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 27. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 28. Canada: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 29. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 30. Canada: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 31. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 32. Canada: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 33. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 34. Canada: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 35. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 36. Canada: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 37. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 38. Canada: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 39. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 40. Mexico: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 41. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 42. Mexico: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 43. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 44. Mexico: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 45. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 46. Mexico: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 47. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 48. Mexico: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 49. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 50. Mexico: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 51. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 52. Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 53. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 54. Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 55. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 56. Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 57. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 58. Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 59. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 60. Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 61. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 62. Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 63. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 64. Germany: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 65. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 66. Germany: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 67. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 68. Germany: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 69. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 70. Germany: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 71. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 72. Germany: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 73. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 74. Germany: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 75. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 76. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 77. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 78. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 79. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 80. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 81. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 82. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 83. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 84. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 85. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 86. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 87. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 88. France: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 89. France: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 90. France: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 91. France: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 92. France: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 93. France: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 94. France: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 95. France: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 96. France: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 97. France: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 98. France: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 99. France: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 100. Italy: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 101. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 102. Italy: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 103. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 104. Italy: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 105. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 106. Italy: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 107. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 108. Italy: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 109. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 110. Italy: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 111. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 112. Spain: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 113. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 114. Spain: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 115. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 116. Spain: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 117. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 118. Spain: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 119. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 120. Spain: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 121. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 122. Spain: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 123. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 124. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 125. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 126. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 127. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 128. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 129. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 130. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 131. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 132. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 133. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 134. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 135. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 136. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 137. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 138. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 139. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 140. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 141. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 142. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 143. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 144. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 145. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 146. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 147. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 148. China: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 149. China: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 150. China: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 151. China: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 152. China: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 153. China: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 154. China: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 155. China: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 156. China: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 157. China: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 158. China: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 159. China: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 160. India: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 161. India: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 162. India: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 163. India: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 164. India: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 165. India: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 166. India: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 167. India: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 168. India: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 169. India: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 170. India: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 171. India: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 172. Japan: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 173. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 174. Japan: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 175. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 176. Japan: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 177. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 178. Japan: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 179. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 180. Japan: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 181. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 182. Japan: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 183. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 184. Australia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 185. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 186. Australia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 187. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 188. Australia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 189. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 190. Australia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 191. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 192. Australia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 193. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 194. Australia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 195. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 196. South Korea: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 197. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 198. South Korea: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 199. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 200. South Korea: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 201. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 202. South Korea: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 203. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 204. South Korea: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 205. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 206. South Korea: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 207. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 208. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 209. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 210. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 211. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 212. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 213. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 214. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 215. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 216. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 217. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 218. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 219. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 220. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 221. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 222. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 223. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 224. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 225. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 226. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 227. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 228. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 229. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 230. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 231. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 232. South Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 233. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 234. South Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 235. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 236. South Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 237. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 238. South Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 239. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 240. South Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 241. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 242. South Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 243. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 244. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 245. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 246. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 247. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 248. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 249. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 250. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 251. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 252. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 253. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 254. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 255. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 256. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 257. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 258. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 259. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 260. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 261. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 262. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 263. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 264. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 265. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 266. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 267. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 268. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 269. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 270. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 271. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 272. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 273. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 274. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 275. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 276. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 277. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 278. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 279. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 280. South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 281. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 282. South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 283. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 284. South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 285. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 286. South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 287. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 288. South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 289. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 290. South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 291. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 292. Brazil: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 293. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 294. Brazil: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 295. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 296. Brazil: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 297. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 298. Brazil: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 299. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 300. Brazil: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 301. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 302. Brazil: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 303. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 304. Argentina: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 305. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 306. Argentina: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 307. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 308. Argentina: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 309. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 310. Argentina: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 311. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 312. Argentina: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 313. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 314. Argentina: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 315. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 316. Rest of South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 317. Rest of South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 318. Rest of South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 319. Rest of South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 320. Rest of South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 321. Rest of South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 322. Rest of South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 323. Rest of South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 324. Rest of South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 325. Rest of South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 326. Rest of South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 327. Rest of South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 328. Glossary of Terms, Vaccines Market
List of Figures
Figure 1. Vaccines Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Vaccines Market Revenue (US$ Million), 2021–2031
Figure 5. Vaccines Market Revenue (US$ Million), 2021–2031
Figure 6. Vaccines Market Share (%) – by Technology (2024 and 2031)
Figure 7. Live Attenuated Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Livestock and Poultry: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Vaccines Market Share (%) – by Disease Indication (2024 and 2031)
Figure 10. Influenza: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Medical Devices: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. Feed Additives: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Vaccines Market Share (%) – by Route of Administration (2024 and 2031)
Figure 14. Veterinary Hospitals: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Clinics: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Others: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 17. North America: Vaccines Market – Revenue, 2021–2031 (US$ Million)
Figure 18. North America: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 19. United States: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 20. Canada: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 21. Mexico: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 22. Europe: Vaccines Market – Revenue, 2021–2031 (US$ Million)
Figure 23. Europe: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 24. Germany: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 25. United Kingdom: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 26. France: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 27. Italy: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 28. Spain: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 29. Rest of Europe: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 30. Asia Pacific: Vaccines Market – Revenue, 2021–2031 (US$ Million)
Figure 31. Asia Pacific: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 32. China: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 33. India: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 34. Japan: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 35. Australia: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 36. South Korea: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 37. Rest of APAC: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 38. Middle East and Africa: Vaccines Market – Revenue, 2021–2031 (US$ Million)
Figure 39. Middle East and Africa: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 40. South Africa: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 41. Saudi Arabia: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 42. United Arab Emirates: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 43. Rest of Middle East and Africa: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 44. South and Central America: Vaccines Market – Revenue, 2021–2031 (US$ Million)
Figure 45. South and Central America: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 46. Brazil: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 47. Argentina: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 48. Rest of South and Central America: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely - analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You'll receive access to the report within 4-6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we'll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we're happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you're considering, and we'll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report's scope, methodology, customization options, or which license suits you best, we're here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we'll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we'll ensure the issue is resolved quickly so you can access your report without interruption.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For